After intravenous injection, the active ingredient, Uromitexan, is soon transformed into a disulfide, and in the renal filtration system is again resumed. As a result, a free thiol compound is formed, which is in contact with the alkylating derivative, to form a non-toxic stable ester.
The limiting half-life is 2-3 hours after intravenous injection.
The half-life of 60 mg per kg in the accelerated phase is 0.17 hours, and in the slowed-down phase, 1.08 hours.
Uromitexane is fully excreted through the kidneys for eight hours.
After oral intake of the tablets, the absorption of Uromitexan begins in the small intestine. The average peak content of metabolites in the urinary fluid is found after 2-4 hours. About 25-35% of the amount used Uromitexan is in the urinary fluid as a free substance for the initial four hours. The amount of 2-4 g per m 2 duration half-toxicant is 5-7 hours.
To keep the required amount of Uromitexan in the urinary system, it is required to observe the appropriate multiplicity of the drug's intake into the body. Biological availability in urinary fluid with internal use of Uromitexan may range from 45 to 79%, relative to availability after intravenous injection.
The presence of dietary masses in the digestive tract does not affect the quality of accessibility of the drug in the urine after ingestion.
After combined intravenous and oral administration of Uromitexan, systemic exposure is increased to 150%, which allows to maintain a constant excretion of the active ingredient within 24 hours.
Approximately 5% of the active ingredient is excreted in the 12-24 hour interval, relative to the intravenous injection. The degree of binding to plasma proteins is from 69 to 75%.
, , , , ,